BOULDER, Colo., Oct. 25, 2016 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2017 and hold a conference call to discuss those results on Tuesday, November 1, 2016. Ron Squarer, Chief Executive Officer, will lead the call.
Tuesday, November 1, 2016
9:00 a.m. Eastern Time
Webcast, including Replay and Conference Call Slides:
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Five registration studies are currently advancing related to three cancer drugs. These programs include binimetinib (MEK162), encorafenib (LGX818) and selumetinib (AstraZeneca).
Array BioPharma Inc.
For more information:
Last updated on: 26/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.